T1	p 25 43	prostatic cancer .
T2	p 162 213	previously untreated patients with prostatic cancer
T3	p 623 696	patients with advanced disease no longer responsive to hormonal treatment
T4	p 807 836	Procarbazine treated patients
T5	i 243 317	Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate
T6	i 343 355	Stilboestrol
T7	i 363 371	Estracyt
T8	i 473 485	Stilboestrol
T9	i 723 733	Adriamycin
T10	i 737 751	Procarbazine .
T11	i 807 819	Procarbazine
T12	o 528 546	objective response
T13	o 550 574	significant side effects
T14	o 586 601	gynaecomastia .
T15	o 752 776	Toxicity and early death